Outcome MeasureMystical Experience

PEQ

Persisting Effects Questionnaire

3 Papers in Blossom

About This Instrument

The Persisting Effects Questionnaire (PEQ) is a self-report measure developed at Johns Hopkins University to assess lasting changes in attitudes, moods, behaviors, and spiritual practices attributed to psychedelic experiences. Administered weeks or months after a session, it captures whether participants perceive enduring positive or negative effects. The PEQ covers changes in personal well-being, life satisfaction, relationships with others, relationship to one’s own body, spirituality/sense of meaning, and behavioral changes. Respondents rate whether changes occurred and their magnitude on a 6-point scale. The PEQ has been particularly informative in the Johns Hopkins healthy volunteer studies (Griffiths et al.), where participants rated psilocybin sessions among the most meaningful and spiritually significant experiences of their lives at 14-month follow-up. It provides unique longitudinal data about the perceived durability and real-world significance of psychedelic-facilitated experiences.

Outcome Data Across Studies

Reported results for PEQ across 3 studies with quantitative data.

Outcome data across 9 study arm–timepoint observations
SD
The peak experience variable in DPT-assisted psychotherapy with cancer patients
1997Secondary
LSD-assisted psychotherapy(experimental)01477.913.4
The peak experience variable in DPT-assisted psychotherapy with cancer patients
1997Secondary
LSD-assisted psychotherapy(experimental)01733.813.4
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
2014Secondary
Psilocybin-assisted(experimental)71449.36.5
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
2014Secondary
Psilocybin-assisted(experimental)141563.24.2
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
2014Secondary
Psilocybin-assisted(experimental)211569.76.0
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
2025Secondary
Psilocybin 25 mg(experimental)21172.61.3
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
2025Secondary
Psilocybin 25 mg(experimental)45.5172.71.1
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
2025Secondary
Psilocybin 25 mg(experimental)63173.10.9
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
2025Secondary
Psilocybin 25 mg(experimental)77173.30.9

Papers Using PEQ

Quick Facts

Full Name
Persisting Effects Questionnaire
Domain
Mystical Experience
Papers Indexed
3
Interpretation
Higher = better
Unit
points
All Measures